Eli Lilly's 3-step strategy to dominate the $95 billion obesity market
1. Eli Lilly aims to dominate the $95 billion obesity market by 2030. 2. Tirzepatide is outperforming competitors in weight loss efficacy. 3. A new pill, orforglipron, may challenge injectable weight loss drugs by 2026. 4. Lilly is developing diverse treatment options addressing various obesity mechanisms. 5. Analysts predict ongoing strong investor interest in Lilly's innovative pipeline.